Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

JOURNAL ARTICLE

Everolimus and pazopanib: two new drugs for renal cell cancer

(no author information available yet)

Medical Letter on Drugs and Therapeutics 2010 May 3, 52 (1337): 33-4

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

You are not logged in. Sign Up or Log In to join the discussion.

Pazopanib in renal cell carcinoma. Cora N Sternberg Clinical Advances in Hematology & Oncology: H&O 2010, 8 (4): 232-3

Pazopanib. Ronald M Bukowski, Uma Yasothan, Peter Kirkpatrick Nature Reviews. Drug Discovery 2010, 9 (1): 17-8

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Guru Sonpavde, Thomas E Hutson, Cora N Sternberg Expert Opinion on Investigational Drugs 2008, 17 (2): 253-61

Pazopanib for the treatment of metastatic renal cell carcinoma. Amy M Pick, Kelly K Nystrom Clinical Therapeutics 2012, 34 (3): 511-20

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Stéphane Oudard, Jacques Medioni, Jorge Aylllon, Eduardo Barrascourt, Reza-Thierry Elaidi, José Balcaceres, Florian Scotte Expert Review of Anticancer Therapy 2009, 9 (6): 705-17

Pazopanib in renal cell carcinoma. James E Ward, Walter M Stadler Clinical Cancer Research 2010 December 15, 16 (24): 5923-7

Pazopanib: therapeutic developments. Suwicha Limvorasak, Edwin M Posadas Expert Opinion on Pharmacotherapy 2009, 10 (18): 3091-102

Make the most of Read.
Download the mobile app.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Read